Gene therapy

BioViva Secures a U.S. Patent for an hTERT and Follistatin Gene-Therapy Approach

U.S. Patent No. 12,653,907 covers methods that combine hTERT and Follistatin-344 for age-related disorders, including approaches tied to telomere length, muscle mass, and blood glucose.

Anton Dalsätt · 3 min read